Press enter to search

Suggested searches

Early Development
Candidate Selection
Late Development
ADME
Translational Pharmaceutics

Resources

Resource centre

Reset filters
12 / 179 resources
Peer Reviewed Publication
CC-99677, A Novel, Oral, Selective Covalent MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production
Dr. Stuart Mair, Global Vice President, Medical, Early Development, has contributed to a scientific article on Arthritis Research & Therapy. Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is activated downstream of p38 MAPK and regulates stability of mRNAs encoding inflammatory cytokines.
Webinar
Non-Clinical vs Clinical: Risks & Considerations When Developing Modified Release Dosage Forms
Dr. Vanessa Zann, Senior Drug Development Consultant, discusses specialized technologies used to optimize modified-release formulations.
Info Sheet
Modified-Release Formulation Strategies
With over 30 years of formulation expertise and over 100 MR programs developed, the team at Quotient Sciences possess the experience, capabilities, and technologies needed to create a successful MR formulation.
Peer Reviewed Publication
New Study Article: Absorption, metabolism and excretion of opicapone in human healthy volunteers
Nand Singh, Medical Director contributions to Bial Study Paper. This paper documents the study - absorption, metabolism and excretion of opicapone (2,5-dichloro-3-(5-[3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide), a selective catechol-O-methyltransferase inhibitor investigations.
Webinar
Getting it Right Early: The Importance of Biopharmaceutics in Early Drug Development
Chris Roe, Quotient Sciences' Principal Research Fellow, discusses strategies for overcoming biopharmaceutic challenges for small molecules in today’s drug development.
Scientific Posters
Why Archiving is a Crucial Part of Any Clinical Trial
A Quotient Sciences Poster by Erika Reategui, Director, GCP Quality Assurance, Quality Assurance: Why Archiving is a Crucial Part of Any Clinical Trial
Webinar
Moving Drug Substance Off the Critical Path: Streamlined Strategies to Accelerate to First-in-Human & Beyond
Watch our on demand webinar to hear Dr. Stephen McQuaker, Director of Drug Development Consulting, as he explores case studies to demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise to get drug substance off the critical path.
Webinar
Overcoming Complex Formulation Challenges: Integrated Strategies for Poor Solubility, Modified Release & Pediatrics
Watch our on-demand webinar featuring John McDermott, VP of Scientific Consulting at Quotient Sciences, who discusses how an integrated program design can simplify development processes for complex molecules and reduce overall costs.
Article
PharmTech - Unlocking Formulation Expertise
As the industry enters a phase where the patents of many major drugs will expire and the use of more novel therapeutic modalities is increasing, the desire to partner up with a company that can offer significant expertise is also rising. A new article featuring Quotient Sciences' Vanessa Zann, Senior Drug Development Consultant and Chris Roe, Principal Research Fellow.
Peer Reviewed Publication
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
Synucleinopathies such as Parkinsońs disease (PD), Dementia with Lewy odies (DLB) and Multiple System Atrophy (MSA) are characterized by deposition of misfolded and aggregated a-synuclein. Small aggregates (oligomers) of a-synuclein have been shown to be the most relevant neurotoxic species and are targeted by anle138b, an orally bioavailable small molecule compound which shows strong disease-modifying effects in animal models of synucleinopathies.
Scientific Posters
A First-in-Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor
Quotient Sciences Poster: A First-in-Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor
Peer Reviewed Publication
A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
Quotient Sciences and Kadmon co-authored scientific publications for their recent NDA approved drug Belumosudil.